Anti-Cxcr3 Antibody Picoband®

Chemokine receptor CXCR3 is a Galphai protein-coupled receptor in the CXC chemokine receptor family. Other names for CXCR3 are G protein-coupled receptor 9 (GPR9) and CD183. It is mapped to Xq13.1. CXCR3 is expressed on malignant B cells from chronic lymphoproliferative disorders, particularly in patients with CLL, and represents a fully functional receptor involved in chemotaxis of malignant B lymphocytes. It is found that in the absence of known etiologic agents, CXCR3 represents a novel target for therapeutic interference early in type 1 diabetes. CXCR3 signaling is associated with MG pathogenesis and proposed that and CXCR3 may serve as novel drug targets to treat MG. CXCR3A and CXCR3B are involved in the chemotactic and vascular effects of CXCL4L1.

Tumor necrosis factor receptor superfamily member 1A; Tumor necrosis factor receptor 1; TNF-R1; Tumor necrosis factor receptor type I; TNF-RI; TNFR-I; p55; p60; CD120a; Tumor necrosis factor receptor superfamily member 1A, membrane form; Tumor necrosis factor-binding protein 1; TBPI; TNFRSF1A; TNFAR; TNFR1

Activated T-cells. Highly expressed on tonsillar T-cells, which are closely associated with B-cells in the apical light zone of germinal centers, the site of terminal B- cell maturation. Expressed at lower levels in thymus, lung, lymph node and peripheral blood leukocytes. Expressed in the medulla of fetal and newborn thymus.

Antiviral Signaling, Apoptosis, Associated Proteins, Cancer, Cell Biology, Cell Death, Growth Factors/Hormones, Immune System Diseases, Immunology, Receptors, Signal Transduction

Receptor for TNFSF2/TNF-alpha and homotrimeric TNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate- specific cysteine proteases) mediating apoptosis. Contributes to the induction of non-cytocidal TNF effects including anti-viral state and activation of the acid sphingomyelinase.

1. Trentin, L., Agostini, C., Facco, M., Piazza, F., Perin, A., Siviero, M., Gurrieri, C., Galvan, S., Adami, F., Zambello, R., Semenzato, G. The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. J. Clin. Invest. 104: 115-121, 1999. 2. Frigerio, S., Junt, T., Lu, B., Gerard, C., Zumsteg, U., Hollander, G. A., Piali, L. Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nature Med. 8: 1414-1420, 2002. 3. Feferman, T., Maiti, P. K., Berrih-Aknin, S., Bismuth, J., Bidault, J., Fuchs, S., Souroujon, M. C. Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. J. Immun. 174: 5324-5331, 2005. 4. Struyf, S., Salogni, L., Burdick, M. D., Vandercappellen, J., Gouwy, M., Noppen, S., Proost, P., Opdenakker, G., Parmentier, M., Gerard, C., Sozzani, S., Strieter, R. M., Van Damme, J. Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood 117: 480-488, 2011.

At -20°C for one year from date of receipt. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freezing and thawing.